Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein

Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?

(2022) Simone Engelender et al.   MOVEMENT DISORDERS

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments

(2022) Matthew E. Gegg et al.   NEUROBIOLOGY OF DISEASE

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

(2022) Johannes Levin et al.   EBioMedicine

Phase 1/1b Studies of UCB0599 , an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

(2022) Johan Willem Smit et al.   MOVEMENT DISORDERS

Monoclonal Antibody Therapy in Parkinson’s Disease — The End?

(2022) Alan Whone   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

(2022) Gennaro Pagano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Cinpanemab in Early Parkinson’s Disease

(2022) Anthony E. Lang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structures of α-synuclein filaments from human brains with Lewy pathology

(2022) Yang Yang et al.   NATURE

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

(2022) Nour Majbour et al.   NEUROLOGY

Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson’s disease

(2022) Hiroaki Sekiya et al.   Acta Neuropathologica Communications

Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study

(2021) Johannes Attems et al.   ACTA NEUROPATHOLOGICA

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

(2021) Tracy A. Cole et al.   JCI Insight

Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques

(2021) Diego Sucunza et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson’s disease brain as revealed by multicolor STED microscopy

(2021) Tim E. Moors et al.   ACTA NEUROPATHOLOGICA

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

(2021) Werner Poewe et al.   Journal of Parkinsons Disease

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

(2021) Luis M. A. Oliveira et al.   npj Parkinsons Disease

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease

(2021) Marco J. Russo et al.   Acta Neuropathologica Communications

Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice

(2020) Natalia Ninkina et al.   NEUROBIOLOGY OF AGING

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

(2019) Miroslaw Brys et al.   MOVEMENT DISORDERS

Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes

(2019) Sarah H. Shahmoradian et al.   NATURE NEUROSCIENCE

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes

(2019) Yaping Chu et al.   BRAIN

Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts

(2019) Timo Strohäker et al.   Nature Communications

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

(2018) John L Robinson et al.   BRAIN

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

(2018) Joseph Jankovic et al.   JAMA Neurology

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity

(2018) Matthew J. Benskey et al.   Frontiers in Molecular Neuroscience

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

(2018) Andreas Weihofen et al.   NEUROBIOLOGY OF DISEASE

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects

(2017) Julianna J. Tomlinson et al.   JOURNAL OF NEURAL TRANSMISSION

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

Genetics of Synucleinopathies

(2017) Robert L. Nussbaum   Cold Spring Harbor Perspectives in Medicine

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

(2016) Dale B. Schenk et al.   MOVEMENT DISORDERS

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain

(2015) Rosalind F. Roberts et al.   BRAIN

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing

(2011) Valerie Cullen et al.   ANNALS OF NEUROLOGY

 -Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies

(2011) Y. Lim et al.   JOURNAL OF NEUROSCIENCE

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

(2011) Eliezer Masliah et al.   PLoS One

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

(2010) Brit Mollenhauer et al.   Biomarkers in Medicine

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

(2009) E. Sidransky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells

(2008) Tereza Vogiatzi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

GATA transcription factors directly regulate the Parkinson's disease-linked gene  -synuclein

(2008) C. R. Scherzer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA